DermTech, Inc. (DMTKQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jul 31, 2025, 8:00 PM EDT

DermTech Company Description

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States.

The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers.

It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions.

In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials.

Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners.

It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

On June 18, 2024, DermTech, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

The plan was later approved as Chapter 11 liquidation on July 17, 2025.

DermTech, Inc.
CountryUnited States
IndustryMedical - Diagnostics & Research
SectorHealthcare
Employees208
CEOBret Christensen

Contact Details

Address:
12340 El Camino Real
San Diego, Delaware 92130
United States
Phone858 450 4222
Websitedermtech.com

Stock Details

Ticker SymbolDMTKQ
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS24984K1051
SIC Code2835

Key Executives

NamePosition
Bret ChristensenChief Executive Officer
Kevin SunChief Financial Officer
Steve KunszaboHead of Investor Relations